Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is treated with bevacizumab at the end of the Roche/Genentech sponsored parent trial and continues to have benefit as judged by the investigator~* Eligible for continuation of bevacizumab treatment at the end of a parent trial, according to parent trial protocol~* Able to comply with this extension study protocol (MO25757)~Exclusion Criteria:~* Evidence of disease progression assessed according to parent trial protocol during the screening phase for this extension study~* Evidence of any adverse event potentially attributable to bevacizumab, for which the local label recommends permanent discontinuation~* A treatment interruption with bevacizumab of more than 42 days since the last administration of bevacizumab in the parent trial~* Evidence of any other disease that would put the participant at high risk for treatment-related complications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Breast Cancer (Type: EXPERIMENTAL): Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
- Ovarian Cancer or Peritoneal Carcinoma (Type: EXPERIMENTAL): Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
- Renal Cell Carcinoma (Type: EXPERIMENTAL): Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
- Colorectal Cancer (Type: EXPERIMENTAL): Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
- Non-Squamous, Non-Small Cell Lung Cancer (Type: EXPERIMENTAL): Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
- Glioblastoma Multiforme (Type: EXPERIMENTAL): Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).